Concepedia

Publication | Open Access

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( <scp>AWARD</scp> ‐8)

DOIFull Paper Access

95

Citations

24

References

2016

Year

Kathleen Dungan, Raimund Weitgasser, Federico Pérez Manghi, Ella Pintilei, Jessie L. Fahrbach, Haochen Jiang, J. Shell, Kenneth E. Robertson
Diabetes Obesity and Metabolism

Abstract

Once-weekly dulaglutide 1.5 mg had a favourable benefit/risk profile when added to glimepiride monotherapy.

References

YearCitations

Page 1